Harith Rajagopalan, Fractyl Health CEO
December 14, 2023 05:40 PM ESTUpdated December 15, 03:44 AM
Financing
Cell/Gene Tx

Bet­ting on pub­lic mar­ket de­mand for more obe­si­ty ther­a­pies, Fractyl Health files for IPO to back gene ther­a­py

Kyle LaHucik

Senior Reporter

A week af­ter one obe­si­ty biotech, Car­mot Ther­a­peu­tics, backed out of its IPO plans in fa­vor of a $2.7 bil­lion sale to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times